Allele-Specific Small Interfering RNA Corrects Aberrant Cellular Phenotype in Keratitis-Ichthyosis-Deafness Syndrome Keratinocytes.


Journal

The Journal of investigative dermatology
ISSN: 1523-1747
Titre abrégé: J Invest Dermatol
Pays: United States
ID NLM: 0426720

Informations de publication

Date de publication:
05 2020
Historique:
received: 20 02 2019
revised: 16 08 2019
accepted: 17 09 2019
pubmed: 11 11 2019
medline: 7 1 2021
entrez: 10 11 2019
Statut: ppublish

Résumé

Keratitis-ichthyosis-deafness (KID) syndrome is a severe, untreatable condition characterized by ocular, auditory, and cutaneous abnormalities, with major complications of infection and skin cancer. Most cases of KID syndrome (86%) are caused by a heterozygous missense mutation (c.148G>A, p.D50N) in the GJB2 gene, encoding gap junction protein Cx26, which alters gating properties of Cx26 channels in a dominant manner. We hypothesized that a mutant allele-specific small interfering RNA could rescue the cellular phenotype in patient keratinocytes (KCs). A KID syndrome cell line (KID-KC) was established from primary patient KCs with a heterozygous p.D50N mutation. This cell line displayed impaired gap junction communication and hyperactive hemichannels, confirmed by dye transfer, patch clamp, and neurobiotin uptake assays. A human-murine chimeric skin graft model constructed with KID-KCs mimicked patient skin in vivo, further confirming the validity of these cells as a model. In vitro treatment with allele-specific small interfering RNA led to robust inhibition of the mutant GJB2 allele without altering expression of the wild-type allele. This corrected both gap junction and hemichannel activity. Notably, allele-specific small interfering RNA treatment caused only low-level off-target effects in KID-KCs, as detected by genome-wide RNA sequencing. Our data provide an important proof-of-concept and model system for the potential use of allele-specific small interfering RNA in treating KID syndrome and other dominant genetic conditions.

Identifiants

pubmed: 31705875
pii: S0022-202X(19)33381-0
doi: 10.1016/j.jid.2019.09.022
pmc: PMC7395648
mid: NIHMS1613077
pii:
doi:

Substances chimiques

Connexins 0
GJB2 protein, human 0
RNA, Small Interfering 0
Connexin 26 127120-53-0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1035-1044.e7

Subventions

Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : NEI NIH HHS
ID : R01 EY013163
Pays : United States
Organisme : NEI NIH HHS
ID : R01 EY026911
Pays : United States
Organisme : Wellcome Trust
ID : WT104076MA
Pays : United Kingdom

Informations de copyright

Copyright © 2019 UCL GOS Institute of Child Health. Published by Elsevier Inc. All rights reserved.

Références

Physiology (Bethesda). 2013 May;28(3):190-8
pubmed: 23636264
Br J Dermatol. 2007 May;156(5):1015-9
pubmed: 17381453
Nat Rev Drug Discov. 2010 Jan;9(1):57-67
pubmed: 20043028
EMBO Mol Med. 2018 Feb;10(2):239-253
pubmed: 29246969
J Gen Physiol. 2013 Jul;142(1):23-35
pubmed: 23797420
J Am Acad Dermatol. 2013 Jul;69(1):127-34
pubmed: 23384797
J Invest Dermatol. 2015 Apr;135(4):1033-1042
pubmed: 25229253
Am J Hum Genet. 2002 May;70(5):1341-8
pubmed: 11912510
J Invest Dermatol. 2001 Oct;117(4):958-64
pubmed: 11676838
Nat Med. 2006 Mar;12(3):348-53
pubmed: 16491086
J Gen Physiol. 2013 Jul;142(1):3-22
pubmed: 23797419
Front Mol Neurosci. 2017 Sep 22;10:298
pubmed: 29018324
Biomol Ther (Seoul). 2017 May 1;25(3):296-307
pubmed: 28365978
Pediatr Dermatol. 1996 Mar-Apr;13(2):105-13
pubmed: 9122065
J Invest Dermatol. 2016 Mar;136(3):574-583
pubmed: 26777423
J Invest Dermatol. 2016 Jan;136(1):225-235
pubmed: 26763442
Am J Physiol Cell Physiol. 2007 Sep;293(3):C1032-48
pubmed: 17615163
J Invest Dermatol. 2015 May;135(5):1338-1347
pubmed: 25625422
J Struct Biol. 2009 Oct;168(1):168-76
pubmed: 19236918
J Invest Dermatol. 2009 Apr;129(4):870-8
pubmed: 18987669
Mol Biol Cell. 2011 Dec;22(24):4776-86
pubmed: 22031297
Invest Ophthalmol Vis Sci. 2005 Jun;46(6):1957-65
pubmed: 15914609
Exp Dermatol. 2012 Aug;21(8):592-8
pubmed: 22643125
Proc Natl Acad Sci U S A. 2012 Jul 24;109(30):11975-80
pubmed: 22773805
BMC Bioinformatics. 2014 Jun 17;15:192
pubmed: 24934636
Am J Pathol. 2006 Aug;169(2):416-23
pubmed: 16877344
Biochim Biophys Acta. 2012 Aug;1818(8):2068-75
pubmed: 22155211
J Cell Sci. 2005 Apr 1;118(Pt 7):1505-14
pubmed: 15769851
J Cell Biol. 1995 May;129(3):805-17
pubmed: 7537274
Curr Gene Ther. 2015;15(5):503-10
pubmed: 26264709
Biochem J. 2006 Mar 15;394(Pt 3):527-43
pubmed: 16492141
Mol Ther. 2011 Feb;19(2):408-16
pubmed: 20877344
Mol Ther Nucleic Acids. 2012 Feb 14;1:e11
pubmed: 23344722
J Control Release. 2014 Dec 28;196:355-62
pubmed: 25449884
Dermatol Ther. 2015 Mar-Apr;28(2):89-93
pubmed: 25546246
J Control Release. 2013 Mar 28;166(3):211-9
pubmed: 23313112
FEBS Lett. 2014 Apr 17;588(8):1304-14
pubmed: 24607543
J Invest Dermatol. 2002 Apr;118(4):724-7
pubmed: 11918723
J Biol Chem. 2017 Jun 9;292(23):9721-9732
pubmed: 28428247
FEBS Lett. 2015 Jul 8;589(15):1904-10
pubmed: 26070424

Auteurs

Ming Yang Lee (MY)

Infection, Immunity and Inflammation Programme/Immunobiology Section, UCL Great Ormond Street Institute of Child Health, London, United Kingdom.

Hong-Zhan Wang (HZ)

Department of Physiology and Biophysics, Stony Brook University, Stony Brook, New York.

Thomas W White (TW)

Department of Physiology and Biophysics, Stony Brook University, Stony Brook, New York.

Tony Brooks (T)

UCL Genomics, UCL Great Ormond Street Institute of Child Health, London, United Kingdom.

Alan Pittman (A)

Molecular Neuroscience, UCL Institute of Neurology, London, United Kingdom; Genetics Research Centre, St George's, University of London, London, United Kingdom.

Heerni Halai (H)

Infection, Immunity and Inflammation Programme/Immunobiology Section, UCL Great Ormond Street Institute of Child Health, London, United Kingdom.

Anastasia Petrova (A)

Infection, Immunity and Inflammation Programme/Immunobiology Section, UCL Great Ormond Street Institute of Child Health, London, United Kingdom.

Diane Xu (D)

Infection, Immunity and Inflammation Programme/Immunobiology Section, UCL Great Ormond Street Institute of Child Health, London, United Kingdom.

Stephen L Hart (SL)

Department of Genetics and Genomic Medicine, UCL Great Ormond Street Institute of Child Health, London, United Kingdom.

Veronica A Kinsler (VA)

Department of Genetics and Genomic Medicine, UCL Great Ormond Street Institute of Child Health, London, United Kingdom; Paediatric Dermatology, Great Ormond Street Hospital for Children, London, United Kingdom.

Wei-Li Di (WL)

Infection, Immunity and Inflammation Programme/Immunobiology Section, UCL Great Ormond Street Institute of Child Health, London, United Kingdom. Electronic address: w.di@ucl.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH